Status:
COMPLETED
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
Lead Sponsor:
AstraZeneca
Conditions:
Advanced Breast Cancer
Eligibility:
FEMALE
18-130 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who pro...
Eligibility Criteria
Inclusion
- Written informed consent
- Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease
- One or more evaluable lesions
Exclusion
- Prior hormonal therapy with fulvestrant
- More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer
- Prior biologic therapy for ABC including Anti-VEGF agents
- Radiation therapy within 4 weeks prior to provision of consent
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00454805
Start Date
March 1 2007
End Date
April 1 2016
Last Update
August 3 2016
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Burbank, California, United States
2
Research Site
Los Angeles, California, United States
3
Research Site
Palm Springs, California, United States
4
Research Site
Boca Raton, Florida, United States